Latest Contract Manufacturing News

DroneShield Limited has reported a landmark first half of 2025, with revenue surging 210% to $72.3 million and securing its largest-ever contract worth $61.6 million, setting the stage for a transformative year.

DroneShield Limited has reported a remarkable turnaround in the half-year ended June 2025, posting record revenue of $72.3 million and a profit after tax of $2.1 million, reversing last year’s loss. The company also secured its largest-ever contract, signaling strong momentum in the counterdrone technology sector.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Elsight Limited has reported a remarkable 344% jump in first-half revenue to US$4.85 million, significantly narrowing its net loss and securing a substantial US$39 million capital raise to fuel growth.

Metal Powder Works has landed a $1 million contract to supply the US Navy with a portable metal powder production system, marking a significant step in defense-focused additive manufacturing.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Electro Optic Systems (EOS) has secured its largest-ever order for the Slinger Counter-Drone system, boosting its contract backlog by 25% to $170 million and reporting strong cash flow and a debt-free balance sheet.

Fluence Corporation reported a robust 64.7% revenue increase in the first half of 2025, driven by strong project execution in Ivory Coast and growth in key business units. Despite tariff uncertainties and a cautious China outlook, the company maintains its full-year guidance and eyes further backlog expansion.

Jatcorp Limited reported a robust 76% revenue increase in Q4 FY25, driven by strong Moroka® sales and expanded manufacturing capabilities, setting ambitious growth targets for FY26.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.